Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 10 de 10
Filtrer
1.
Cell Biochem Biophys ; 2024 Jul 29.
Article de Anglais | MEDLINE | ID: mdl-39078538

RÉSUMÉ

Systemic lupus erythematosus (SLE) is a classic autoimmune disease characterized by abnormal autoantibodies, immune complex deposition, and tissue inflammation. Despite extensive research, the exact etiology and progression of SLE remain elusive. Cytidine/uridine monophosphate kinase 2 (CMPK2), a mitochondrial nucleoside monophosphate kinase, has garnered attention for its potential involvement in the development of various diseases, including SLE, where it has been observed to be dysregulated in affected individuals. However, the specific involvement of CMPK2 in the pathogenesis of SLE remains unclear. This study aims to clarify the expression level of CMPK2 in SLE CD4+ T cells and explore its impact on CD4+ T cells. The expression levels of the CMPK2 gene and the corresponding CMPK2 protein in CD4+ T cells of SLE patients were quantified using RT-qPCR and Western blot, respectively. Immunofluorescence and RT-qPCR were used to assess the mitochondrial function of SLE CD4+ T cells. Flow cytometry was used to assess CD4+ T cell activation and apoptosis levels. The impact of CMPK2 on CD4+ T cells was investigated by gene transfection experiment. We found that CMPK2 was significantly upregulated in SLE CD4+ T cells at both gene and protein levels. These cells demonstrated aberrant mitochondrial function, as evidenced by elevated mitochondrial reactive oxygen species (mtROS) levels, mitochondrial membrane potential, and mitochondrial DNA (mtDNA) copy number. Flow cytometry revealed a notable increase in both apoptosis and activation levels of CD4+ T cells in SLE patients. Gene transfection experiments showed that suppressing CMPK2 led to a significant improvement in these conditions. These findings suggest that CMPK2 may be involved in the pathogenesis of SLE by regulating mitochondrial dysfunction in CD4+ T cells and thus affecting CD4+ T cell activation and apoptosis. Our study may provide a new target for the treatment of SLE.

2.
Front Immunol ; 13: 978851, 2022.
Article de Anglais | MEDLINE | ID: mdl-36059547

RÉSUMÉ

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that involves multiple organs. However, the current SLE-related biomarkers still lack sufficient sensitivity, specificity and predictive power for clinical application. Thus, it is significant to explore new immune-related biomarkers for SLE diagnosis and development. Methods: We obtained seven SLE gene expression profile microarrays (GSE121239/11907/81622/65391/100163/45291/49454) from the GEO database. First, differentially expressed genes (DEGs) were screened using GEO2R, and SLE biomarkers were screened by performing WGCNA, Random Forest, SVM-REF, correlation with SLEDAI and differential gene analysis. Receiver operating characteristic curves (ROCs) and AUC values were used to determine the clinical value. The expression level of the biomarker was verified by RT‒qPCR. Subsequently, functional enrichment analysis was utilized to identify biomarker-associated pathways. ssGSEA, CIBERSORT, xCell and ImmuCellAI algorithms were applied to calculate the sample immune cell infiltration abundance. Single-cell data were analyzed for gene expression specificity in immune cells. Finally, the transcriptional regulatory network of the biomarker was constructed, and the corresponding therapeutic drugs were predicted. Results: Multiple algorithms were screened together for a unique marker gene, MX2, and expression analysis of multiple datasets revealed that MX2 was highly expressed in SLE compared to the normal group (all P < 0.05), with the same trend validated by RT‒qPCR (P = 0.026). Functional enrichment analysis identified the main pathway of MX2 promotion in SLE as the NOD-like receptor signaling pathway (NES=2.492, P < 0.001, etc.). Immuno-infiltration analysis showed that MX2 was closely associated with neutrophils, and single-cell and transcriptomic data revealed that MX2 was specifically expressed in neutrophils. The NOD-like receptor signaling pathway was also remarkably correlated with neutrophils (r >0.3, P < 0.001, etc.). Most of the MX2-related interacting proteins were associated with SLE, and potential transcription factors of MX2 and its related genes were also significantly associated with the immune response. Conclusion: Our study found that MX2 can serve as an immune-related biomarker for predicting the diagnosis and disease activity of SLE. It activates the NOD-like receptor signaling pathway and promotes neutrophil infiltration to aggravate SLE.


Sujet(s)
Lupus érythémateux disséminé , Marqueurs biologiques , Réseaux de régulation génique , Humains , Lupus érythémateux disséminé/diagnostic , Lupus érythémateux disséminé/génétique , Lupus érythémateux disséminé/immunologie , Protéines de résistance aux myxovirus/génétique , Protéines de résistance aux myxovirus/immunologie , Protéines NLR/métabolisme , Transcriptome
3.
Int J Biol Sci ; 18(7): 3034-3047, 2022.
Article de Anglais | MEDLINE | ID: mdl-35541910

RÉSUMÉ

5'-Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the methionine salvage pathway and has been reported to suppress tumorigenesis. The MTAP gene is located at 9p21, a chromosome region often deleted in breast cancer (BC). However, the clinical and biological significance of MTAP in BC is still unclear. Here, we reported that MTAP was frequently downregulated in 41% (35/85) of primary BCs and 89% (8/9) of BC cell lines. Low expression of MTAP was significantly correlated with a poor survival of BC patients (P=0.0334). Functional studies showed that MTAP was able to suppress both in vitro and in vivo tumorigenic ability of BC cells, including migration, invasion, angiogenesis, tumor growth and metastasis in nude mice with orthotopic xenograft tumor of BC. Mechanistically, we found that downregulation of MTAP could increase the polyamine levels by activating ornithine decarboxylase (ODC). By treating the MTAP-repressing BC cells with specific ODC inhibitor Difluoromethylornithine (DFMO) or treating the MTAP-overexpressing BC cells with additional putrescine, metastasis-promoting or -suppressing phenotype of these MTAP-manipulated cells was significantly reversed, respectively. Taken together, our data suggested that MTAP has a critical metastasis-suppressive role by tightly regulating ODC activity in BC cells, which may serve as a prominent novel therapeutic target for advanced breast cancer treatment.


Sujet(s)
Tumeurs du sein , Ornithine decarboxylase , Purine nucleoside phosphorylase , Animaux , Tumeurs du sein/enzymologie , Tumeurs du sein/génétique , Tumeurs du sein/métabolisme , Régulation négative , Femelle , Hétérogreffes , Humains , Souris , Souris nude , Ornithine decarboxylase/métabolisme , Purine nucleoside phosphorylase/génétique , Purine nucleoside phosphorylase/métabolisme
4.
Adv Healthc Mater ; 11(6): e2101496, 2022 03.
Article de Anglais | MEDLINE | ID: mdl-34878725

RÉSUMÉ

The major obstacles of anti-PD therapy in metastatic tumors are limited drug delivery in primary tumors and metastatic foci, and the lack of tumor-infiltrating lymphocytes (TILs). Here, the authors constructed a novel cellular membrane nanovesicles platform (M/IR NPs) based on homologous targeting and near-infrared (NIR) responsive release strategy to potentiate PD-1/PD-L1 blockade therapy against metastatic tumors. In tumor-bearing mice, biomimetic M/IR NPs targeted both primary tumors and their lung metastases. Upon laser irradiation, M/IR NPs reduced cancer-associated fibroblasts (CAFs) in tumor microenvironment, thus increasing the penetration of TILs. When shed from homologous tumor cell membranes, positively charged nanoparticles (IR NPs) core can capture released tumor-associated antigens, thereby enhancing the antigen-presenting ability of DCs to activate cytotoxic T lymphocytes. When the photothermal conversion temperature under NIR-laser is higher than 42 °C, M/IR NPs initiated the rupture of cell membranes and the responsive release of PD-1/PD-L1 inhibitor BMS, which significantly attenuated tumor-associated immunosuppression and synergistically induced T cellular immunity to inhibit the tumor growth and metastasis. Overall, biomimetic M/IR NPs can improve the targeting and therapeutic efficacy of anti-PD therapy in primary tumors and metastases, opening up a new avenue for the diagnosis and treatment of metastatic tumors in the future.


Sujet(s)
Nanoparticules , Tumeurs , Animaux , Lignée cellulaire tumorale , Systèmes de délivrance de médicaments , Immunothérapie , Souris , Tumeurs/traitement médicamenteux , Microenvironnement tumoral
5.
Cancer Lett ; 522: 238-254, 2021 12 01.
Article de Anglais | MEDLINE | ID: mdl-34571084

RÉSUMÉ

The response rate of anti-PD therapy in most cancer patients remains low. Therapeutic drug and tumor-infiltrating lymphocytes (TILs) are usually obstructed by the stromal region within tumor microenvironment (TME) rather than distributed around tumor cells, thus unable to induce the immune response of cytotoxic T cells. Here, we constructed the cationic thermosensitive lipid nanoparticles IR780/DPPC/BMS by introducing cationic NIR photosensitizer IR-780 iodide (IR780) modified lipid components, thermosensitive lipid DPPC and PD-1/PD-L1 inhibitor BMS202 (BMS). Upon laser irradiation, IR780/DPPC/BMS penetrated into deep tumor, and reduced cancer-associated fibroblasts (CAFs) around tumor cells to remodel the spatial distribution of TILs in TME. Interestingly, the cationic IR780/DPPC/BMS could capture released tumor-associated antigens (TAAs), thereby enhancing the antigen-presenting ability of DCs to activate cytotoxic T lymphocytes. Moreover, IR780/DPPC/BMS initiated gel-liquid crystal phase transition under laser irradiation, accelerating the disintegration of lipid bilayer structure and leading to the responsive release of BMS, which would reverse the tumor immunosuppression state by blocking PD-1/PD-L1 pathway for a long term. This combination treatment can synergistically exert the antitumor immune response and inhibit the tumor growth and metastasis.


Sujet(s)
Antigène CD274/immunologie , Liposomes/pharmacologie , Tumeurs/traitement médicamenteux , Récepteur-1 de mort cellulaire programmée/immunologie , Acétamides/composition chimique , Acétamides/pharmacologie , Antigène CD274/antagonistes et inhibiteurs , Lymphocytes T CD8+/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Prolifération cellulaire/effets des médicaments et des substances chimiques , Humains , Tolérance immunitaire/effets des médicaments et des substances chimiques , Immunothérapie/méthodes , Indoles/composition chimique , Indoles/pharmacologie , Liposomes/composition chimique , Photothérapie de faible intensité , Lymphocytes TIL/effets des médicaments et des substances chimiques , Lymphocytes TIL/effets des radiations , Nanoparticules/composition chimique , Tumeurs/immunologie , Tumeurs/anatomopathologie , Tumeurs/radiothérapie , Récepteur-1 de mort cellulaire programmée/antagonistes et inhibiteurs , Pyridines/composition chimique , Pyridines/pharmacologie , Lymphocytes T cytotoxiques/effets des médicaments et des substances chimiques , Lymphocytes T cytotoxiques/effets des radiations , Microenvironnement tumoral/effets des médicaments et des substances chimiques
6.
J Asian Nat Prod Res ; 21(6): 522-527, 2019 Jun.
Article de Anglais | MEDLINE | ID: mdl-29665732

RÉSUMÉ

A new natural product, 3α,19-dihydroxyl-ent-pimara-8(14),15-diene (1), which possesses an α-orientation hydroxymethyl at C-4 and ∆8,14 groups, as well as eight known compounds, was isolated from the rhizomes of Ricinus communis. The structure of 1 was elucidated by extensive spectroscopic methods and its absolute configurations were confirmed by X-ray crystallographic analysis. The inhibitory rate of 1 against protein tyrosine phosphatase 1B (PTP1B) was 49.49% at the concentration of 6.58 × 10-5 mol/L.


Sujet(s)
Diterpènes/composition chimique , Diterpènes/pharmacologie , Antienzymes/composition chimique , Antienzymes/pharmacologie , Protein Tyrosine Phosphatase, Non-Receptor Type 1/antagonistes et inhibiteurs , Ricinus/composition chimique , Animaux , Cristallographie aux rayons X , Hypoglycémiants/composition chimique , Hypoglycémiants/pharmacologie , Souris , Conformation moléculaire , Structure moléculaire , Rhizome/composition chimique
7.
Int J Pharm ; 460(1-2): 119-30, 2014 Jan 02.
Article de Anglais | MEDLINE | ID: mdl-24275447

RÉSUMÉ

Liposomes containing bile salts (BS-liposomes) significantly enhanced the oral bioavailability of insulin (rhINS). However, the underlying absorption mechanisms have not been well understood yet. In this study, the transiting fate of the liposomes was first investigated using fluorescent imaging tools to confirm the effect of enhanced gastrointestinal stability. In order to obtain evidence of enhanced transcellular permeation, the interaction between BS-liposomes and the biomembrane was investigated in Caco-2 cell lines. BS-liposomes were found to be more stable in the gastrointestinal tract by showing prolonged residence time in comparison with conventional liposomes. BS-liposomes were significantly more effective for cellular uptake and transport of rhINS; and this effect was found to be size- and concentration-dependent. A good linear correlation was observed between the concentration of the liposomes and uptake/transport of rhINS. Confocal laser scanning microscopy visualization further validated the transcellular transit of BS-liposomes. The BS-liposomes showed little effect on cytotoxicity and did not induce apoptosis within 24h investigation. It was concluded that BS-liposomes showed improved in vivo residence time and enhanced permeation across the biomemebranes. Mechanisms of trans-enterocytic internalization could be proposed as an interpretation for enhanced absorption of insulin-loaded liposomes.


Sujet(s)
Tube digestif/métabolisme , Insuline/pharmacocinétique , Protéines recombinantes/pharmacocinétique , Administration par voie orale , Animaux , Apoptose/effets des médicaments et des substances chimiques , Acides et sels biliaires/composition chimique , Cellules Caco-2 , Survie cellulaire/effets des médicaments et des substances chimiques , Humains , Insuline/administration et posologie , Absorption intestinale , Liposomes , Mâle , Rats , Rat Wistar , Protéines recombinantes/administration et posologie
8.
Zhongguo Zhong Yao Za Zhi ; 38(2): 167-70, 2013 Jan.
Article de Chinois | MEDLINE | ID: mdl-23672035

RÉSUMÉ

OBJECTIVE: To establish a HPLC-DAD method for the determination of axifolin, naringenin, quercetin and kaempferol in Cudrania tricuspidata and C. cochinchinensis in order to provide a scientific reference for species identification and quality evaluation, by establishing. METHOD: The determination was performed by HPLC-DAD on an Agilent C18 column (4.6 mm x 150 mm, 5 microm) by gradient elution (0-15 min, 35%-50% A; 15-30 min, 50% - 65% A) using methanol (A) and 0.1% phosphoric acid (B) as the mobile phase. The flow rate was 1 mL x min(-1). The detection wavelength was 290 nm for taxifolin and naringenin, 365 nm for quercetin and kaempferol with column temperature at 30 degrees C. RESULT: The content of axifolin and quercetin in the root of C. tricuspidata were remarkably higher than that in the root of C. cochinchinensis, and the content in stem of C. tricuspidata was also higher than that in the stem of C. cochinchinensis, the content of axifolin and quercetin was variable in different species. The content of naringenin and kaempferol in the root of C. cochinchinensis was visibly higher than that in the root of C. tricuspidata, and the content in the stems of the two herbs was similar, the content of naringenin and kaempferol was visibly variable in different medicinal parts of the herb, but similar between the two herbs. CONCLUSION: There's some difference of the content of the four ingredients in different medicinal parts and different herbs, so clinical use should not be confused.


Sujet(s)
Chromatographie en phase liquide à haute performance/méthodes , Médicaments issus de plantes chinoises/isolement et purification , Flavones/isolement et purification , Moraceae/composition chimique , Médicaments issus de plantes chinoises/composition chimique , Flavanones/composition chimique , Flavanones/isolement et purification , Flavones/composition chimique , Kaempférols/composition chimique , Kaempférols/isolement et purification , Méthanol , Spécificité d'organe , Acides phosphoriques , Racines de plante/composition chimique , Tiges de plante/composition chimique , Plantes médicinales , Quercétine/analogues et dérivés , Quercétine/composition chimique , Quercétine/isolement et purification , Reproductibilité des résultats , Spécificité d'espèce
9.
Zhongguo Zhong Yao Za Zhi ; 38(17): 2779-81, 2013 Sep.
Article de Chinois | MEDLINE | ID: mdl-24380297

RÉSUMÉ

OBJECTIVE: To find out the correlation between the content of taxifolin in Polygonum orientale and the storage time. METHOD: HPLC was used to determine taxifolin. The chromatographic condition was as following: Diamonsil C18 column (4.6 mm x 200 mm, 5 microm), mobile phase acetonitrile -0.1% phosphoric acid (gradient elution), the detection wavelength 290 nm and flow rate 1.0 mL x min(-1), the column temperature 30 degrees C. RESULT: The injection volume of taxifolin was in good linearity within 0.07 and 0.35 microg, the average recovery was 99.7% with RSD 0.2%. Taxifolin content was 0.84, 1.36, 1.75, 1.99 mg x g(-1) corresponding to storage time of 10, 7, 6, 5 years, respectively. CONCLUSION: The content of taxifolin decreased with the storage time. When the storage period is more than six years, the content is lower than that required by Chinese Pharmacopoeia (2010 version). This method has a good repeatability and accuracy, it provides a scientific reference for clinical use and quality evaluation of P. orientale.


Sujet(s)
Stockage de médicament/méthodes , Médicaments issus de plantes chinoises/analyse , Polygonum/composition chimique , Quercétine/analogues et dérivés , Chromatographie en phase liquide à haute performance , Stabilité de médicament , Quercétine/analyse
10.
Toxicol In Vitro ; 27(2): 714-20, 2013 Mar.
Article de Anglais | MEDLINE | ID: mdl-23220290

RÉSUMÉ

This study was designed to investigate the cytotoxicity of bile salt-lecithin mixed micelles on the Caco-2 cell model. Cell viability and proliferation after mixed micelles treatments were evaluated with the MTT assay, and the integrity of Caco-2 cell monolayer was determined by quantitating the transepithelial electrical resistance and the flux of tracer, FITC-dextran 4400. The apoptosis induced by mixed micelles treatments was investigated with the annexin V/PI protocol. The particle size of mixed micelles was all smaller than 100 nm. The mixed micelles with lower than 0.2mM sodium deoxycholate (SDC) had no significant effects on cell viability and proliferation. When the level of SDC was higher than 0.4mM and the lecithin/SDC ratio was lower than 2:1, the mixed micelles caused significant changes in cell viability and proliferation. Furthermore, the mixed micelles affected tight junctions in a composition-dependent manner. Specifically, the tight junctions were transiently opened rather than damaged by the mixed micelles with SDC of between 0.2 and 0.6mM. The mixed micelles with more lecithin also induced less apoptosis. These results demonstrate that relatively higher concentrations of mixed micelles are toxic to Caco-2 cells, while phospholipids can attenuate the toxicity of the bile salts.


Sujet(s)
Acide désoxycholique/toxicité , Lécithines/toxicité , Micelles , Apoptose , Cellules Caco-2 , Prolifération cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Acide désoxycholique/administration et posologie , Humains , Lécithines/administration et posologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE